Health Care·Pharmaceuticals·$789.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.78 | N/A | -12.26% |
management commentary, guidance changes, and full analysis available with Pro.
| -12.26% |
Tone: Defensive
Overall, management expressed caution regarding recent performance. They highlighted ongoing challenges but maintained a focus on future opportunities.
Management acknowledged the challenges faced in the quarter.
They emphasized a focus on long-term growth despite current setbacks.
This earnings report indicates that Eli Lilly faced challenges in the fourth quarter of 2007, resulting in an EPS miss. The lack of guidance may leave investors uncertain about the company's future performance. The stock reaction is currently not available, but the miss on EPS could lead to negative sentiment among investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MCDONALDS CORP
Jan 28, 2008